Compare Mesoblast Limited (MESO) vs NRG Energy Inc (NRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs NRG Energy Inc — how do they compare? Mesoblast Limited trades at $14.33 (market cap $1.75B), while NRG Energy Inc trades at $107.03 (market cap $22.35B). The key difference: NRG Energy Inc is far larger — about 12.8× Mesoblast Limited's market cap, and NRG Energy Inc pays a 1.79% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and NRG Energy Inc for 62 Days on average.
| MESO | NRG | |
|---|---|---|
Market Cap | $1.75B | $22.35B |
Volume | 239,027 | 5,011,942 |
Sector | Health | Utilities |
52-Week High | $20.96 | $184.03 |
52-Week Low | $13.19 | $95.23 |
Typical Hold Time | 14 Days | 62 Days |
Enterprise Value | $1.83B | $46.30B |
Dividend Yield | — | 1.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% with bearish technical signals from moving averages. The company reported substantial revenue growth to $120 million in 2026 but remains unprofitable with a -47.82% net margin. Recent FDA approval for Ryoncil potency assay and completion of Phase 3 back pain trial represent significant operational milestones. Cash position remains strong at $161.16 million, though debt levels require monitoring.
While MESO shows promising revenue growth and pipeline progress, persistent losses and negative ROE present fundamental challenges. Analyst consensus leans bullish with 45% buy ratings, but technical indicators suggest near-term caution. The stock offers speculative growth potential contingent on successful commercialization and path to profitability.
NRG Energy (NRG) trades at $108.61, up 4.84% today, with a bullish technical signal and strong analyst consensus. Recent earnings showed a Q2 2026 miss but the company is executing a growth strategy including a 1.2 GW Texas data-center power project. Financials indicate solid revenue of $30.71B in 2025, though net margins are thin at 2.56%, and cash flow trends are volatile with a projected net outflow in 2026.
The outlook is positive given high analyst buy ratings and a $202.90 price target, but risks include execution on large capital projects, rising debt levels, and competitive pressures. Earnings growth from new assets and customer relationships remains the key catalyst for upside, though the stock faces near-term volatility from recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About NRG Energy Inc
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →
